CRLBF
Cresco Labs Inc.
$0.8200
-0.49%
No data for this timeframe.
Vol
SEC Reports1
Exchange OTC·Sector Medicinal Chemicals & Botanical Products·Inc. A1·CIK 0001832928·Prev Close $0.8240
Price Targets
Historical data — last covering-analyst action Aug 2024. No current recommendation available.
$2.00 (Aug 2024)
Current $0.8200
Low $2.00
Median $2.00
High $2.00
1 analysts
$2.00
$2.00
Analyst Ratings
3Strong Buy
12Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 12, 2024 | Needham | REITERATE | Hold |
| Jun 12, 2024 | Zuanic & Associates | INITIATE | Overweight |
| May 16, 2024 | Wedbush | MAINTAIN | Outperform → Outperform |
| May 16, 2024 | Needham | REITERATE | Hold → Hold |
| Mar 14, 2024 | Roth MKM | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.04 | $-0.04 — $-0.04 | -123% YoY | 1 |
| Next Q | $-0.03 | $-0.03 — $-0.03 | -442% YoY | 1 |
| Current FY | $-0.09 ▲ +8.7% | $-0.09 — $-0.09 | -823% YoY | 1 |
| Next FY | $-0.06 ▲ +44.7% | $-0.06 — $-0.15 | 33% YoY | 2 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 6.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Aug 2024): 94% buy across 16 analysts — 3 strong buy, 12 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Aug 2024. No current recommendation available.
$2.00 mean target (Aug 2024)
$2.00 Low
$2.00 High
| Metric | Value |
|---|---|
| Current Price | $0.8200 |
| Target Low | $2.00 |
| Target Mean | $2.00 |
| Target Median | $2.00 |
| Target High | $2.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.04 | $-0.04 | $-0.04 | -123.5% | — | — | $0.2B | 1.6% | 1 |
| Next Q 2026-09-30 |
$-0.03 | $-0.03 | $-0.03 | -442.5% | — | — | $0.2B | 2.1% | 1 |
| Current FY 2026-12-31 |
$-0.09 | $-0.09 | $-0.09 | -822.6% | +8.7% | 1↑ 0↓ | $0.7B | -0.2% | 1 |
| Next FY 2027-12-31 |
$-0.06 | $-0.06 | $-0.15 | 33.5% | +44.7% | — | $0.7B | 2.3% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.040 | |
| 7d ago | $0.000 | -0.040 |
| 30d ago | $0.000 | -0.040 |
| 60d ago | $0.000 | -0.040 |
| 90d ago | $0.000 | -0.040 |
8 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 7 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 12, 2024 | Needham | REITERATE | — | Hold |
| Jun 12, 2024 | Zuanic & Associates | INITIATE | — | Overweight |
| May 16, 2024 | Wedbush | MAINTAIN | Outperform | Outperform |
| May 16, 2024 | Needham | REITERATE | Hold | Hold |
| Mar 14, 2024 | Roth MKM | MAINTAIN | Neutral | Neutral |
| Mar 20, 2023 | Wedbush | MAINTAIN | — | Outperform |
| Feb 24, 2023 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Dec 30, 2022 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Dec 20, 2022 | Cowen & Co. | DOWNGRADE | Outperform | Market Perform |
| Dec 2, 2022 | Wedbush | INITIATE | — | Outperform |
| Aug 18, 2022 | Piper Sandler | MAINTAIN | — | Overweight |
| Aug 18, 2022 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Mar 24, 2022 | Piper Sandler | MAINTAIN | — | Overweight |
| Nov 15, 2021 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Nov 3, 2021 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Aug 5, 2021 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Jul 7, 2021 | Jefferies | INITIATE | — | Buy |
| Jan 20, 2021 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Nov 19, 2020 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Oct 30, 2020 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Aug 21, 2020 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Jun 12, 2020 | Needham | INITIATE | — | Hold |
| May 29, 2020 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| May 27, 2020 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Apr 28, 2020 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Mar 30, 2020 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Feb 14, 2020 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Sep 13, 2019 | Cowen & Co. | INITIATE | — | Outperform |
| Aug 13, 2019 | Piper Sandler | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 12 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 3 | 12 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 3 | 12 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 3 | 12 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 3 | 12 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 3 | 12 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.